


























Study with the several resources on Docsity
Earn points by helping other students or get them with a premium plan
Prepare for your exams
Study with the several resources on Docsity
Earn points to download
Earn points by helping other students or get them with a premium plan
Community
Ask the community for help and clear up your study doubts
Discover the best universities in your country according to Docsity users
Free resources
Download our free guides on studying techniques, anxiety management strategies, and thesis advice from Docsity tutors
A study guide for the NR566 final exam. It covers topics such as hormone replacement therapy, progestin-only contraception, and androgen therapy. The document also discusses the most effective forms of contraception and the effects of CYP450 inhibitors or inducers on oral contraceptives. It includes information on the administration and benefits of testosterone replacement therapy and the treatment of delayed puberty and hypogonadism. a useful resource for nursing students preparing for the NR566 final exam.
Typology: Exams
1 / 34
This page cannot be seen from the preview
Don't miss anything!
- Prevention of osteoporosis with hormone replacement therapy Tara (p.433) Hormone therapy reduces postmenopausal bone loss and thereby decreases the risk for osteoporosis and related fractures. Therapy is lifelong and the risk for harm is increased. Hormone therapy should only be considered for women with significant risk for osteoporosis, and only when that risk outweighs the risks of hormone therapy. Meds are: raloxifene (Evista), bisphosphonates (e.g., alendronate {Fosamax}), calcitonin (Miacalin), and teriparatide (Forteo). Encourage patients to prevent bone loss by ensuring adequate intake of calcium and Vit D, performing regular weight-bearing exercises, and avoiding smoking and excessive alcohol use. - When and when not to use progestin for hormone replacement therapy and why Tara (p.430-432) When : Menopausal hormone therapy Why : The primary noncontraceptive use of progestins is to counteract the adverse effects of estrogen on the endometrium in women undergoing menopausal HT. When : Dysfunctional uterine bleeding Why : Heavy irregular bleeding that occurs when progesterone levels are insufficient to balance the stimulatory influence of estrogen on the endometrium. Treatment goals with administration of progestins are to stop the bleeding and establish a regular monthly cycle. When: Amenorrhea Why: Progestins can induce menstrual flow in selected women who are experiencing amenorrhea. When: Endometrial hyperplasia and carcinoma Why: Progestins can provide palliation in women with metastatic endometrial carcinoma, but they do not prolong life. Endometrial hyperplasia, a potentially precancerous condition, can be suppressed with progestins. Benefits derive from counteracting the proliferative effects of estrogen. When: Other uses - Supports early pregnancies, prevention of preterm birth (Makena) Why: Progestins can be used to support early pregnancy in women with corpus luteum deficiency syndrome and in women undergoing in vitro fertilization (IVF). One progestin (hydroxyprogesterone acetate (Makena) is approved for preventing preterm birth in
women with a singleton pregnancy and a history of preterm delivery. When not to: Women with no uterus Why: Do not prescribe progestins to women who have undergone a hysterectomy.
immediately; hence no backup contraception is needed. With a Sunday start, which is done to have menses occur on weekdays rather than the weekend, protection may not be immediate; hence an alternate form of birth control should be used during the first 7 days of the pill pack. With both options, each dose should be taken at the same time every day (e.g., with a meal or at bedtime). Successive dosing cycles should commence every 28 days even if there is breakthrough bleeding or spotting. Pg 441 o What teaching needs to be done Educate patients on proper protocol for missed doses (depending on medication type and cycle). Effectiveness of oral contraceptives can be reduced with some medications, including certain common antibiotics. Pg 446 o What baseline data is needed? Assess for history of hypertension, diabetes, thromboembolism, cerebrovascular or cardiovascular disease, breast cancer. Urine pregnancy test. Pg 446 o Contraindications for OCs Contraindications to use include current pregnancy, history of thromboembolus, breast cancer, and women over 35 years of age who continue to smoke tobacco. Use with caution in women with diabetes, hypertension, and cardiac disease. Pg 446
- How to achieve an extended cycle with oral contraceptives Jennifer Jacques To achieve an extended schedule, the user would simply purchase four packets of a 28-day product (each of which contains 21 active pills) and then take the active pills for 84 days straight. Pg 442 - What behaviors would make one birth control method more effective over another? Akunna Aguwa o Be able to evaluate a patient scenario and suggest an appropriate birth control method (type of prescribed contraception: OC, long-term methods, IUD, etc)
Page 437-438: Among women of higher weight oral contraceptive’s efficacy is somewhat reduced. Possible reasons include decreased blood levels of the hormones, sequestration in adipose tissue, and altered metabolism. Combination oral should be avoided by women with certain cardiovascular disorders as well as by women older than 35 years old who smoke. An alternative method is preferred: diaphragm, progestin-only pill, or IUD.
- What effect does CYP450 inhibitors or inducers have on OCs? Akunna Aguwa o Recall examples of CYP450 inhibitors and inducers from NR565 (Chapter 4 in textbook) o How does this impact prescribing of OCs? Page 441 : CYP450 inducers like Phenytoin, carbamazepine, Rifampin, alcohol and sulfonylureas can accelerate OC metabolism and thereby reduce OC effects. Women taking OC in combination with any of these agents should be alert for indications of reduced OC blood levels, such as breakthrough bleeding or spotting. It may be necessary to either:
o Effects ▪ Therapeutic - Endogenous androgens are responsible for key functions in the body such as the normal growth and maturation of sex organs, skeletal growth, activation of sebaceous glands during puberty, as well as enhancing the production of erythropoietic stimulating factor for red blood cell production and contributing to libido. ▪ Adverse - Hot flashes, bone fractures, disturbed libido, insulin resistance, erectile dysfunction, gynecomastia, acne, HTN, LDL Increase, HDL decrease, menstrual disturbances, sterility, hepatotoxicity, mood swings/ aggression. o Monitoring Needs- Lipids, blood glucose, androgen levels such as testosterone monitoring, Prostate specific antigen testing, H&H, CBC, BMP o Role of androgens in treating anemia - Androgen therapy will increase bone marrow stimulation to make more RBCs.
- Preferred administration route of alprostadil and why Shelby Bernaix Alprostadil is usually shot directly INTO the penis in order to achieve an erection. The medication comes as a power that is then mixed with water and inserted via syringe. Can also be administered IV in a hospital setting. - Treatment of hypogonadism Haley Herrera o Benefits o Administration methods for transdermal preparations Oral Androgens Only two androgens are approved for oral therapy of male hypogonadism. Despite the advantages of cost and ease of administration, these are not first-line agents. The androgenic effects of oral androgens are erratic. Furthermore, both fluoxymesterone and methyltestosterone are 17-α-alkylated androgens and therefore pose a risk for hepatotoxicity. Accordingly they should not be used long term. Transdermal Testosterone Testosterone is available in three transdermal formulations: patch, gel, and liquid. With all three formulations, testosterone is absorbed through the skin and then slowly absorbed into the blood.
Androgen INDICATIONS Hypogonadism (Male) Replacement Therapy (Male) Delayed Puberty (Male) Catabolic States Testosterone and Testosterone Esters Testoste rone
Testoste rone cypionat e
Testoste rone enantha te
17-α-Alkylated Androgens Fluoxym esteron e
Methylt estoster one
Oxandro lone
Male Hypogonadism
also delay BPH progression. Benefits take months to develop. α 1 Blockers Selective α1a Blockers Silodosin Rapaflo Blockade of α1a receptors relaxes smooth muscle in the bladder neck, prostate capsule, and prostatic urethra, and thereby decreases dynamic obstruction of the urethra. Benefits develop rapidly. Abnormal ejaculation (ejaculation failure, reduced ejaculate volume, retrograde ejaculation). Risk of floppy-iris syndrome during cataract surgery. Tamsulosi n Flomax Nonselective α 1 Blockers Alfuzosin Uroxatr al, Xatral Same as the selective α1a blockers. Hypotensio n, fainting, dizziness,
Doxazosi n Cardura , Cardura XL somnolence , and nasal congestion (from blocking α 1 receptors on blood vessels) Terazosin Hytrin Phosphodiesterase-5 Inhibitor Tadalafil Cialis Smooth muscle relaxation in the bladder, prostate, and urethra Hypotensio n, priapism α1a Blocker/5-α-Reductase Inhibitor Tamsulosi n/dutaste ride Jalyn Combination of the effects of 5-α- reductase inhibitors and selective α1a blockers Decreased libido and abnormal ejaculation (ejaculation failure, reduced ejaculate volume, retrograde ejaculation) o Therapeutic Effects -Two 5-α-reductase inhibitors are available: finasteride and dutasteride. Both drugs can reduce prostate size, although several months are required for a noticeable effect. There is no proof that one drug works better than the other.
c. Rotigotine – PATCH FOR EARLY-STAGE PD, 2MG/WEEK THEN INCREASE, DO NOT PLACE ON SAME SIDE (TRANS PATCH)
**2. COMT inhibitor
The ability to measure serum levels of anticonvulsants has been a significant advance in the treatment of epilepsy. This technique enables practitioners to monitor a patient's plasma concentration, to detect potential toxicity, and to assess compliance with the prescribed regimen. o Patient teaching & Drug Interactions ▪ Phenytoin - Used for partial seizures and primary general tonic-clonic seizures. It was the first drug to suppress seizures without depressing the entire CNS. Mechanism of Action is it blocks sodium channels but limits to blocking sodium channels in hyperactive neurons. Treatment for all major forms of epilepsy except absent seizures. First drug of choice for adults and older children. Medication needs to be discontinued gradually or patient is at risk of seizures. Phenytoin Dosage Considerations: Dosing is highly individualized. Plasma drug levels are often monitored as an aid to establishing dosage. The dosing objective is to produce levels between 10 and 20 μg/mL. Levels below 10 μg/mL are too low to control seizures; levels above 20 μg/mL produce toxicity. Because phenytoin has a relatively narrow therapeutic range (between 10 and 20 μg/mL), and because of the nonlinear relationship between phenytoin dosage and phenytoin plasma levels, after a safe and effective dosage has been established, the patient should adhere to it rigidly Adverse effects include CNS side effects such as Nystagmus (continues back-and-forth movement of eyes), sedation, ataxia, diplopia, and cognitive impairment. Others are gingival hyperplasia (excessive growth of gum tissue), some patient require gingivectomy (removal of excess gum tissue) but can be prevented by good oral hygiene, flossing and gum massage. May need to supplement folic acid to reduce growth. Morbilliform (Measles-like) rash can develop and progress into Stevens-Johnson syndrome or toxic epidermal necrolysis (TEN). Check patients of Asian decent for human leukocyte antigen (HLA-B*1502) which is a genetic mutation known to develop this issues and should not be prescribed phenytoin.
- Management of Migraines Trina LHeureux o 1 st line therapy ▪ Preventative – FOR PTS WITH 3 OR MOMRE MIGRAINE ATTACKES QMONTH 1. propanolol and metoprolol – 1 st^ line drug for migraine prevention 2. antiepileptic drugs a. divalporex – black box warning: fatal pancreatitis, hepatitis, neural tube defects 3. topiramax – migraine prophylaxis; its benefits appear equal to those of the first line beta blockers
effects are dizziness, headaches, and confusion and only occur 5-7% of the time in those taking it. Less common side effects include diarrhea or constipation.Adjust dose for renal impairment with creatinine clearance of less than 30mL/min. Avoid using it in patients with severe hepatic impairment or corneal conditions as they have worsened during treatment. ▪ Rivastigmine/ EXELON- Unlike donepezil, which causes reversible inhibition of AChE, rivastigmine causes irreversible inhibition. rivastigmine can cause peripheral cholinergic side effects but occurs more often than the others. With oral dosing, the most common cholinergic effects are nausea, vomiting, diarrhea, abdominal pain, tremors, and anorexia. Weight loss (7% of initial weight) occurs in 18% of male to 26% of female patients. By enhancing cholinergic transmission, rivastigmine can intensify symptoms in patients with peptic ulcer disease, bradycardia, sick sinus syndrome, urinary obstruction, and lung disease; caution is advised. Like other drugs in this class, rivastigmine can cause bradycardia, fainting, falls, and fall-related fractures. No significant drug interactions because it does not interact with hepatic drug-metabolizing enzymes. CHANGE PATCH Q2WEEKS (S/E: INCREASE CHOLINESTERASE)
▪ Cholinesterase Inhibitors- nausea, vomiting, diarrhea and dyspepsia often occur. Dizziness and headache also occur frequently. Can cause bronchoconstriction so use caution in patients with asthma or COPD. Cardiac effects are uncommon but include bradycardia, fainting, and falls. These patients may require a pacemaker or to withdrawl the drug.
- Additional Notes o If phenytoin (NOT FOR PREGGOS!!!) is administered in doses only slightly greater than those needed for therapeutic effects, the liver's capacity to metabolize the drug will be overwhelmed, causing plasma levels of phenytoin to rise dramatically. This unusual relationship between dosage and plasma levels is illustrated in Fig. 21.1A. As you can see, after plasma levels have reached the therapeutic range, small changes in dosage produce large changes in plasma levels. As a result, small increases in dosage can cause toxicity, and small decreases can cause therapeutic failure. This relationship makes it difficult to establish and maintain a dosage that is both safe and effective. For this reason, serum drug levels and trough levels are often used, along with assessments of seizure control, to determine dosage. PHENYTOIN LEVEL - 10-20 MG NEED TO TAPER OFF ; ABRUPT WITHDRAWAL CAN CAUSE SEIZURES!! IF PT ON TUBE FEEDING, TURN OFF PUMP 1H BEFORE AND AFTER ADMIN ▪ Examples: If a patient is taking phenytoin 300mg daily for seizures and their serum concentration is 8mg/L and they experience a considerable increase in seizure activity, their dose would only need to increase to 350mg daily. o When on medications for Alzheimer’s Disease (AD) and symptoms increase, it is better to increase the AD medication than to add things like herbal medications, vitamins, or NSAIDs **Week 7
o Monitoring (pp. 230-231) ▪ Lithium: Lithium has a low therapeutic index. As a result, toxicity can occur at blood levels only slightly greater than therapeutic levels. Accordingly, the monitoring of lithium levels is mandatory & an essential component of treatment. Lithium levels must be kept below 1.5 mEq/L--levels greater than this can produce significant toxicity. Lithium levels should range from 0.4 to 1 mEq/L. Generally levels should be between 0.6 & 0.8 mEq/L as these levels are effective for most patients. Levels of 0.8 to 1 mEq/L may be more effective but carry a greater risk of adverse effects. Blood for lithium determinations should be drawn in the morning, 12 hours after the evening dose. Lithium levels should be measured every 2-3 days during initial therapy & every 3-6 months during maintenance. BLACK BOX WARNING: Lithium toxicity is closely related to serum lithium levels & can occur at doses close to therapeutic levels. Facilities for prompt & accurate serum lithium determinations should be available before initiating therapy. Signs of Lithium Toxicity: Less than 1.5 mEq/L: N/V/D, thirst, polyuria, lethargy, slurred speech, muscle weakness, fine hand tremor. 1.5-2 mEq/L: Persistent GI upset, coarse hand tremor, confusion, hyperirritability of muscles, EKG changes, sedation, incoordination. 2-2.5 mEq/L: Ataxia, giddiness, high output of dilute urine, serious EKG changes, fasciculations, tinnitus, blurred vision, clonic movements, seizures, stupor, severe hypotension, coma, death (usually secondary to pulmonary complications). More than 2.5: Symptoms may progress rapidly to generalized convulsions, oliguria, & death.
- Management of Major Depressive Disorder (pp. 214-216) Drugs are the primary therapy for major depression. However, benefits are limited mainly to patients with severe depression. In patients with mild to moderate depression, antidepressants have little or no beneficial effect. Available antidepressants fall into 5 major classes: ***selective serotonin reuptake inhibitors (SSRIs) *serotonin-norepinephrine reuptake inhibitors (SNRIs) *tricyclic antidepressants (TCAs) monoamine oxidase inhibitors (MAOIs) atypical antidepressants
EACH CLASS. Differences among these drugs relate mainly to side effects & drug interactions. o Know example drugs ▪ SSRIs: The most commonly prescribed antidepressants, they are indicated for major depression as well as several other psychological disorders. Compared with the TCAs & MAOIs, they are equally effective, better tolerated, & much safer. They work by blocking 5-HT reuptake & thereby increase 5-HT in the synapse. (pp. 216-219) Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Paroxetine (Paxil) Sertraline (Zoloft) Vortioxetine (Trintellix) o Adverse Effects ▪ Venlafaxine (Effexor XR) : The 1st serotonin-norepinephrine reuptake inhibitor (SNRI) available & the prototype drug for this class of antidepressants. (pp. 219-220) Venlafaxine can cause a variety of adverse effects. The most common is nausea (37% to 58%), followed by headache, anorexia, nervousness, sweating, somnolence, & insomnia. Dose-dependent weight loss may occur secondary to anorexia. It can also cause dose-related sustained diastolic hypertension , so blood pressure should be monitored. Sexual dysfunction may also occur. Some patients experience sustained mydriasis , which can increase the risk for eye injury in those with elevated intraocular pressure or glaucoma. Like the SSRIs, venlafaxine can cause hyponatremia , especially in older adult patients taking diuretics. Like all other antidepressants, it may increase the risk for suicide , especially in children & young adults. The combined use of venlafaxine with MAOIs & other serotonergic drugs increases the risk for serotonin syndrome , a potentially fatal reaction. Because of this, use with an MAOI is contraindicated. MAOIs should be withdrawn at least 14 days before starting venlafaxine. When switching from venlafaxine to an MAOI, venlafaxine should be discontinued 7 days before starting the MAOI.